

1 **Title:** Magnetofluidic platform for rapid multiplexed screening of SARS-CoV-2 variants and respiratory  
2 pathogens

3 **Authors:** Alexander Y. Trick<sup>1\*</sup>, Fan-En Chen<sup>1\*</sup>, Liben Chen<sup>2\*\*</sup>, Pei-Wei Lee<sup>2</sup>, Alexander C. Hasnain<sup>1</sup>, Heba  
4 H. Mostafa<sup>3</sup>, Karen C. Carroll<sup>3</sup>, Tza-Huei Wang<sup>1,2,4\*\*</sup>

5 \*Co-first author

6 \*\*Co-corresponding author

7 <sup>1</sup>Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

8 <sup>2</sup>Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

9 <sup>3</sup>Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of  
10 Medicine, Baltimore, MD 21205, USA

11 <sup>4</sup>Institute for NanoBiotechnology, Johns Hopkins University, Baltimore, MD 21218, USA

## 12 **Abstract**

13 The rise of highly transmissible SARS-CoV-2 variants brings new challenges and concerns with  
14 vaccine efficacy, diagnostic sensitivity, and public health responses in the fight to end the pandemic.  
15 Widespread detection of variant strains will be critical to inform policy decisions to mitigate further  
16 spread, and post-pandemic multiplexed screening of respiratory viruses will be necessary to properly  
17 manage patients presenting with similar respiratory symptoms. In this work, we have developed a  
18 portable, magnetofluidic cartridge platform for automated PCR testing in <30 min. Cartridges were  
19 designed for multiplexed detection of SARS-CoV-2 with either distinctive variant mutations or with  
20 Influenza A and B. The platform demonstrated a limit of detection down to 2 copies/ $\mu$ L SARS-CoV-2 RNA  
21 with successful identification of B.1.1.7 and B.1.351 variants. The multiplexed SARS-CoV-2/Flu assay was  
22 validated using archived clinical nasopharyngeal swab eluates ( $n = 116$ ) with an overall  
23 sensitivity/specificity of 98.1%/95.2%, 85.7%/100%, 100%/98.2%, respectively, for SARS-CoV-2, Influenza  
24 A, and Influenza B. Further testing with saliva ( $n = 14$ ) demonstrated successful detection of all SARS-CoV-  
25 2 positive samples with no false-positives.

## 26 **Introduction**

27 While the development and distribution of vaccines brings hope for a return to normalcy,  
28 extensive diagnostic testing remains critical to curbing the spread of the SARS-CoV-2 virus<sup>1-3</sup>. Even with  
29 vaccines, the rise of highly transmissible virus variants that have dominated recent coronavirus disease  
30 2019 (COVID-19) outbreaks raises concerns about mutations leading to potential escape from vaccine  
31 protection<sup>4-6</sup>. Insufficient screening and surveillance has left public health officials with large gaps in  
32 knowledge of the extent and impact of these variants<sup>7</sup>. Furthermore, demand for testing will continue  
33 after the pandemic wanes, as it is predicted that COVID-19 will maintain circulation alongside other  
34 seasonal or endemic respiratory viruses presenting with similar symptoms, such as influenza<sup>8</sup>. Multiplexed  
35 diagnostic screening for detection of SARS-CoV-2 variants and other respiratory pathogens must be made  
36 widely accessible to provide targeted treatments to patients and notify policy makers if more stringent  
37 measures are needed to control transmission.

38 Broad identification of virus variants and infectious pathogens can be achieved with genomic  
39 sequencing, but the necessary equipment and data processing required to conduct sequencing  
40 procedures is currently prohibitively expensive and complex for universal adoption<sup>9</sup>. Instead of  
41 sequencing, nucleic acid amplification tests (NAATs) typically used for infectious disease diagnosis may be  
42 readily modified to detect characteristic sequences of variants<sup>10</sup>. Although relatively easy to implement  
43 compared to sequencing, the increase in demand for NAATs during the SARS-CoV-2 pandemic has  
44 revealed severe deficiencies in public access to infectious disease diagnostics and aggravated existing  
45 shortages in testing capacity, supplies, and laboratory personnel<sup>11</sup>.

46 The gold standard NAATs for detection of SARS-CoV-2 RNA and other respiratory viruses use  
47 reverse-transcription polymerase chain reaction (RT-PCR)<sup>12</sup>. These tests provide the greatest sensitivity  
48 and specificity, but often require transport to high complexity laboratories in centralized test facilities  
49 which can lead to large backlogs with turnaround times of days or weeks<sup>11,13</sup>. Test results should ideally  
50 be delivered on-site at the testing location to facilitate recording of accurate surveillance data and to  
51 enable immediate notification of the test results to the patient for initiating quarantine or linkage to care.  
52 Currently available rapid NAAT platforms use expensive instruments and test cartridges making rapid  
53 screening for a large population with these systems unrealistic. Because of the long turnaround times and  
54 high cost per test of current NAAT platforms, many strategies for large scale testing opt for cheaper  
55 antigen tests<sup>14</sup>. Compared to PCR, these viral antigen tests have reduced sensitivity, higher rates of false-  
56 positives, and are not easily amenable to multiplexed detection of several genetic targets or  
57 pathogens<sup>15,16</sup>.

58 To address the need for affordable and accessible multiplexed NAATs with a fast turnaround time,  
59 we developed an imaging-based portable droplet magnetofluidic cartridge platform. Instead of traditional  
60 fluidic strategies for sample handling and assay automation, droplet magnetofluidic technologies use the  
61 movement of magnetic beads through discrete droplets of reagents to capture, purify, and transfer  
62 analytes for amplification and/or detection<sup>17-20</sup>. Recent developments of magnetofluidic cartridges have  
63 integrated static assay reagents isolated by immiscible liquid barriers into a low-cost plastic disposable<sup>21-</sup>  
64 <sup>23</sup>. Magnetic transfer of beads along a hydrophobic surface within the cartridges obviates the need for  
65 precision fluidic channels and flow controllers that increase the complexity and cost of other automated  
66 NAAT platforms<sup>24,25</sup>. While previous studies using magnetofluidic cartridges were limited to a single  
67 reaction well per cartridge, this work achieves higher levels of multiplexed detection through a  
68 combination of duplexed PCR probe assays and a novel multi-elution aliquoting scheme to distribute  
69 nucleic acids.

70 Testing with our platform's disposable cartridges enables sample-to-answer RT-PCR in under 30  
71 minutes with detection of up to 4 genetic targets per test. Two different assay cartridges were designed  
72 – one for SARS-CoV-2 detection and differentiation of its variants, and another for multiplexed screening  
73 of SARS-CoV-2 with Influenza A, and Influenza B. We demonstrated the utility of our cartridge assays by  
74 testing with extracted RNA from clinical samples, nasopharyngeal swab eluates, and saliva samples. This  
75 platform presents a potent opportunity to expand access to screening SARS-CoV-2 variants and  
76 multiplexed respiratory pathogen testing in any setting with minimal training and immediate on-site  
77 reporting of results.


## 78 **Results**

### 79 ***Assay design and workflow***

80 To conduct a test, the sample is first mixed with a buffer containing functionalized magnetic beads  
81 followed by loading the entire mixture into the sample port of the cartridge. Once sealed with an adhesive  
82 tab to prevent leakage of the sample, the cartridge is inserted into a slot in the side of the instrument (Fig.  
83 1a, Supplementary Fig. 1). Identifying information for the sample is entered by the user using the  
84 instrument's touchscreen interface followed by full automation of nucleic acid extraction, purification,  
85 and amplification by RT-PCR. The instrument conducts real-time analysis of fluorescent signals with fully  
86 interpreted results displayed on the screen in under 30 minutes. Each instrument has a compact footprint  
87 (14.5 cm x 21.6 cm x 14.5 cm) and built-in wireless connectivity for potential integration with laboratory  
88 information systems.

89 We designed two different cartridge assays (Fig. 1b-c) for either detection of SARS-CoV-2 variants  
90 of concern, or multiplexed diagnosis of SARS-CoV-2 with Influenza A and B. Both cartridges employ two  
91 duplexed PCR assays in separate wells containing hydrolysis probes labelled with FAM or Cy5/TYE  
92 fluorophores for a total of 4 target sequences per cartridge. To ensure cartridge reagents are functional  
93 and sample processing is fully completed, each cartridge assay detects a synthetic control RNA sequence<sup>26</sup>  
94 that is pre-mixed in the magnetic bead solution. Detection of SARS-CoV-2 and control RNA are duplexed  
95 in the first well in both assays. A conserved nucleocapsid gene (N1) target sequence was adopted for  
96 universal detection of SARS-CoV-2<sup>27</sup>.

97 The cartridge for discrimination of SARS-CoV-2 variants uses the second PCR well for primers and  
98 probes designed by Vogel et al.<sup>10</sup> to detect the presence of distinct mutations in the SARS-CoV-2 spike  
99 ( $\Delta$ 69-70) and ORF1a ( $\Delta$ 3675-3677) genes (Fig. 1b). The  $\Delta$ 69-70 mutation is associated uniquely with the  
100 B.1.1.7. variant that has shown high transmissibility.<sup>4,5</sup> Meanwhile, the ORF1a deletion is found in B.1.1.7,  
101 B.1.351, and P.1 variants of concern<sup>10</sup>. Therefore, if both the spike and the ORF1a mutation are present,  
102 the virus is classified as B.1.1.7. If the spike mutation is not detected, but the ORF1a mutation is, then the  
103 virus is classified as potentially B.1.351 or P.1. The PCR probes produce an amplification signal in virus  
104 lineages *not* included within the variants of concern, while signal dropout occurs if the described  
105 mutations are present. In the second cartridge designed for multiplexed detection of SARS-CoV-2 with  
106 influenza A and B, the second PCR well instead contains a duplex assay containing primers and probes for  
107 influenza A and B detection<sup>28-30</sup> (Fig. 1c).



108

109 **Fig. 1 | Cartridge platform operation.** a, Nasal swab eluate or saliva is injected directly into the cartridge with  
110 magnetic beads followed by sealing the cartridge and inserting it into the instrument. After magnetofluidic sample  
111 preparation and PCR, the instrument reports the assay results on the built-in touchscreen within 30 minutes. b, Each  
112 PCR well contains two fluorescent probes in the FAM (green/left) or Cy5 (red/right) spectrum. Cartridges include a  
113 duplexed assay for the conserved N1 SARS-CoV-2 sequence and control RNA in the first well. The cartridge designed  
114 for detection of SARS-CoV-2 variants includes a duplexed PCR assay in the second well with probes spanning regions  
115 that contain deletions found in variants of concern. A lack of amplification in the second well indicates the presence  
116 of a mutation and can be used to classify the type of variant present. c, Cartridges designed for multiplexed detection  
117 of respiratory pathogens have a duplexed Influenza A and Influenza B PCR assay in the second well.

### 118 **Magnetofluidic cartridge design**

119 The thermoplastic cartridge design in this work builds upon previous developments of  
120 magnetofluidic cartridges by incorporating greater flexibility in sample input volume, higher multiplexing  
121 of biomarkers, and more robust construction for easier handling<sup>21-23</sup>. Construction of the cartridges uses  
122 simple lamination techniques of three layers that have been laser-cut and thermoformed (Supplementary  
123 Fig. 2). All reagents are pre-loaded into extruded thermoformed wells of the cartridge (Fig. 2a) except for  
124 the magnetic beads which are mixed with the sample prior to loading into the cartridge. An immiscible  
125 layer of silicone oil provides an evaporation barrier and a fluidic interconnect between reagent wells for  
126 transfer of the magnetic beads. By isolating the reagents in thin-walled thermoformed wells, the thermal  
127 mass of the reaction can be spatially isolated for targeted, rapid thermocycling leading to faster  
128 turnaround times than traditional bulky PCR systems.


129 Once the sample is mixed with the magnetic bead buffer and loaded into the cartridge, the viral  
130 particles are lysed with surfactant and heating in the first well to allow for electrostatic binding of viral  
131 RNA to the charge-functionalized magnetic beads (Fig. 2b). Transfer of the beads into the second well  
132 exchanges the beads into a pH neutral wash buffer for removal of binding salts and any contaminants in  
133 the sample which may inhibit PCR (Fig. 2c). Finally, sequential transfer of the beads into the alkaline (pH

134 8.5) PCR wells allows for neutralization of the bead coating and partial release of captured RNA into each  
135 PCR reaction well (Fig. 2d) for amplification and fluorescence detection. To achieve under 30-minute  
136 turnaround time, sample preparation from lysis to completion of elution takes around 6 minutes, followed  
137 by 5 minutes of reverse transcription, and 50 cycles of PCR thermocycling in under 18 minutes (Fig. 2e).

138 The cartridge in this work includes several key innovations. A wax plug between the sample well  
139 and wash well seals off the oil and downstream reagents to immobilize all downstream fluids during  
140 transport and handling, which allows for full range of tilting and shaking the cartridge without reagent  
141 leakage. After the user injects the sample into the cartridge port, any excess sample can escape into an  
142 overflow reservoir and the port is sealed with an adhesive strip to provide an additional layer of safety  
143 from sample contamination and spill of infectious materials.

144 The most critical innovation in this work is the inclusion of an additional PCR well for higher levels  
145 of multiplexing coupled with a sequential elution strategy. Sequential elution takes advantage of the  
146 incomplete release of captured nucleic acids to aliquot RNA into separate reaction buffers. As the beads  
147 are exposed to each new buffer, the captured nucleic acids will be released until an equilibrium between  
148 the concentration of analyte on the bead surface and in the reaction buffer is reached. We have  
149 demonstrated this technique has potential to expand multiplexing up to at least six separate reactions  
150 (Supplementary Fig. 3). This flexibility in multiplexing provides an option to expand future cartridges to  
151 include additional targets for other SARS-CoV-2 variants or for a larger panel of pathogens.





152

153 **Fig. 2 | Cartridge design.** **a**, The magnetofluidic cartridge contains preloaded assay reagents for sample purification  
 154 and PCR. A layer of silicone oil fills the space within the cartridge between reagents, and a wax plug prevents the  
 155 reagents from leaking during transport such that the first well remains empty for loading the sample. **b**, The first  
 156 well is heated to 100°C for 80 seconds (i) to promote viral lysis for RNA capture and to release the wax plug at the  
 157 base of the sample well to allow passage of magnetic beads. **c**, Bead transfer into the wash well (ii) promotes removal  
 158 of salts, proteins, and other sample components that may inhibit PCR. **d**, Bead transfer into the PCR wells  
 159 accompanied by heating to 55°C (iii, iv) allows sequential elution of the captured RNA. **e**, Plot of the temperature of  
 160 previously described steps for sample preparation followed by one-pot reverse transcription and PCR with real-time  
 161 2-color fluorescence detection of both reaction wells at each cycle.


### 162 **Instrument design and sample processing**

163 The instrument contains all components necessary for transfer of magnetic beads through the  
 164 cartridge, temperature control to melt wax seals and conduct RT-PCR, and optics for fluorescence  
 165 excitation and detection (Fig. 3a-b). Instead of complex fluidics, valves, and pressure controllers typically  
 166 found in microfluidic instrumentation, the components here include primarily low-cost hobby servo  
 167 motors and off-the-shelf LED and CMOS camera parts (Supplementary Table 1). Once the cartridge is  
 168 inserted into the instrument, it is detected with the CMOS camera, which uses the fluorescent outline of  
 169 the PCR wells to determine if the cartridge is properly positioned. The fluorescence detection uses dual  
 170 bandpass filters over the CMOS camera for emission, and over a 2-color LED for excitation to permit multi-

171 color detection without moving parts by alternating blue and red LED illumination for FAM and Cy5/TYE  
172 fluorophores, respectively. Three servo motors automate application of the heat blocks to the cartridge  
173 and magnetic bead transfer (Supplementary Fig. 4). If the cartridge has been inserted fully, then the first  
174 servo motor involved rotates a shaft to mount both the sample heat block and PCR heat block onto the  
175 cartridge. With the heat blocks mounted, a power resistor heats the sample heat block to 100°C for 80  
176 seconds to both promote viral lysis and melt the wax plug which then floats toward the top of the cartridge  
177 leaving a clear passage for transfer of the magnetic particles (Fig. 3c).

178 A second servo motor swivels two opposing neodymium permanent magnets to the bottom or  
179 top of the cartridge to pellet beads into reagent wells or extract them into the oil layer. The third servo  
180 motor translates this magnet arm along the length of the cartridge for transfer of the beads between wells  
181 through the oil (Supplementary Video 1). This magnetic transfer paradigm allows the beads to be  
182 transferred anywhere along the long axis of the cartridge for compatibility with cartridge designs  
183 constructed with varying well number, dimensions, and positioning. With the wax melted, the beads are  
184 collected out of the sample well to the top of the cartridge and transferred into the wash buffer well to  
185 remove contaminants that might inhibit function of the downstream PCR assays (Fig. 3d). After alternate  
186 application of the top and bottom magnets for three repeated exchanges of the beads into and out of the  
187 wash buffer, the beads are finally transferred sequentially into the PCR wells (Fig. 3e). Each well receives  
188 the beads for 1 minute while the PCR buffers are heated to 55°C to facilitate release of the capture RNA  
189 and initiate reverse transcription. This multi-elution strategy permits some control over the release of  
190 RNA with higher elution temperature providing a higher fraction of RNA recovered in each well (Fig. 3f).

191 Immediately after elution, generation of cDNA and amplification is carried out with reverse  
192 transcription and PCR thermocycling. Temperature in both wells is simultaneously controlled by the PCR  
193 heat block with 2 second holds at 100°C for cDNA denaturation followed by 2 seconds at 55°C for  
194 annealing and extension. Miniaturization of the PCR heat block's thermal mass and the use of copper's  
195 high thermal conductivity (~400 W/m-K) enables rapid changes in temperature powered by a heatsinked  
196 thermoelectric element (Supplementary Fig. 5). The optimized heat block has temperature ramp rates  
197 ranging between 6 to 10°C/s for both heating and cooling. When combined with time required for  
198 denaturation and annealing holds, controlled approaches to targeted temperatures, and image capture  
199 for fluorescence detection, this rapid thermocycling leads to completion of 50 cycles of PCR in less than  
200 18 minutes.



201


202 **Fig. 3 | Instrumentation for automated sample preparation and multi-elution.** **a**, Fluorescence detection optics and  
 203 heat blocks assembly. **b**, Servo motor arrangement for (1) mounting heat blocks onto the cartridge, (2) swiveling  
 204 magnets to the top and bottom of the cartridge for bead extraction and introduction into wells, and (3) translating  
 205 the magnet arm along the cartridge for bead transfer between wells. **c**, Rotation of the heat blocks mounts them  
 206 onto the cartridge followed by sample well heating to promote sample lysis and melt the wax seal. **d**, Translation of  
 207 the top magnet from the sample well to the wash well followed by swiveling the magnet arm to swap the bottom  
 208 magnet into close proximity with the cartridge pulls the beads into the wash buffer. **e**, Sequential transfer of beads  
 209 into the first PCR well and then the second elutes captured RNA into both reactions. **f**, The first elution releases more  
 210 RNA than the second elution with tunable release of the overall fraction of RNA by changing temperature of the  
 211 buffer during elution. Both elution steps were run in triplicate at each temperature condition and shown here fit  
 212 with a linear regression with 95% confidence interval bands.

### 213 **Assay cartridge analytical sensitivity and specificity**

214 Throughout thermocycling, the CMOS camera takes a picture of the PCR wells for each  
 215 fluorescence channel at the end of each cycle's annealing step (Fig. 4a). The pixel intensity for each well  
 216 is isolated and averaged to generate a real-time fluorescence curve (Fig. 4b), from which the cycle  
 217 threshold (Ct) is determined with an automated thresholding algorithm (Supplementary Fig. 6). Detection  
 218 of amplification and Ct calculation is conducted at the end of each cycle during the test for live reporting  
 219 of results to the user. For high viral load samples (Ct <20), detection of targets may be reported within 18  
 220 minutes from insertion of the cartridge into the instrument.



221 Using the respiratory panel cartridge design, 50  $\mu\text{L}$  samples containing serial dilutions of  
222 inactivated SARS-CoV-2, influenza A, or influenza B viral particles were loaded into cartridges with  
223 magnetic bead solutions. Each dilution was run in triplicate. Both SARS-CoV-2 and Influenza A were  
224 detectable in all replicates down to 2 copies/ $\mu\text{L}$  of sample (Figs. 4c-f), while Influenza B was detected  
225 down to 24 copies/ $\mu\text{L}$  of sample (Figs. 4g, h). We also demonstrated detection of SARS-CoV-2 spiked  
226 into saliva with a limit of detection of 12.5 copies/ $\mu\text{L}$  (Supplementary Fig. 7). To assess the specificity of  
227 the assay, the cartridges were run using a panel of 14 viral and bacterial pathogens (Supplementary Table 2).  
228 No cross-reactive false-positive amplification was detected for any pathogens in the specificity testing panel.



229  
230 **Fig 4| Cartridge PCR fluorescence curves and analytical sensitivity.** a, Fluorescence images of PCR wells in the FAM  
231 and Cy5 channels taken at the annealing step for each cycle with corresponding real-time fluorescence curves  
232 plotted in (b). Solid lines and dotted lines in (b) correspond to the top and bottom wells respectively. Standard curves

233 with Ct values and corresponding average of triplicate fluorescence curves with standard error are shown for SARS-  
234 CoV-2 (c-d), influenza A (e-f), and influenza B (g-h).

### 235 **Clinical sample validation**

236 Using the cartridge for detection of SARS-CoV-2 variants we evaluated clinical samples from Johns  
237 Hopkins Hospital (JHH) as well as extracted RNA from B.1.1.7 and B.1.351 variants. All samples were  
238 previously classified by sequencing using the ARTIC protocol<sup>31</sup> into three categories as either (1) B.1.1.7,  
239 (2) B.1.351/P.1, or (3) Other, indicating sample did not possess the characteristic mutations of current  
240 variants of concern (Table 1). All JHH samples ( $n = 4$ ) amplified N1, ORF1a, and spike targets indicating  
241 they were not one of the variants of concern. Samples previously classified as B.1.1.7 variants ( $n = 4$ ) by  
242 sequencing produced fluorescent amplification signals for N1 on cartridge, but no amplification of either  
243 the ORF1a or the spike targets and were accordingly classified properly. The samples characterized as  
244 B.1.351 ( $n = 3$ ) by sequencing produced signals for N1 and spike, but did not amplify the ORF1a target  
245 resulting in proper classification as B.1.351 or P.1.

246 **Table 1. Detection of SARS-CoV-2 Variants**

Sample	N1-Ct	ORF1a-Ct	Spike-Ct	Classification
JHH #1	30.39	32.57	32.64	Other
JHH #2	30.78	34.44	33.85	Other
JHH #3	28.73	38.10	27.49	Other
JHH #4	28.33	45.57	27.54	Other
B.1.1.7 #1	26.03	Not detected	Not detected	B.1.1.7
B.1.1.7 #2	32.03	Not detected	Not detected	B.1.1.7
B.1.1.7 #3	34.38	Not detected	Not detected	B.1.1.7
B.1.1.7 #4	30.13	Not detected	Not detected	B.1.1.7
B.1.351 #1	33.03	Not detected	37.59	B.1.351 or P.1
B.1.351 #2	28.29	Not detected	37.59	B.1.351 or P.1
B.1.351 #3	32.78	Not detected	31.49	B.1.351 or P.1


247

248 To assess performance of the respiratory pathogen panel cartridges, we tested clinical swab  
249 eluates ( $n = 116$ ) and passive drool saliva ( $n = 14$ ). As a comparator assay, samples were first assessed with  
250 a benchtop assay adapted from the CDC recommended protocol (Supplementary Fig. 8)<sup>32</sup>. Of the swab  
251 samples, 54 were positive for SARS-CoV-2, 14 were Flu A positive, and 4 were Flu B positive using cutoff  
252 Ct values at 45, 49, and 47 respectively. Saliva samples contained 7 SARS-CoV-2 positives all of which were  
253 correctly classified with the cartridge assay. Only one of the SARS-CoV-2 samples went undetected in  
254 cartridge, which was a swab eluate with a relatively late Ct (37.2) by the benchtop comparator assay  
255 indicating a low viral titer. Of the negative SARS-CoV-2 swab samples, three false-positives were detected  
256 using cartridges, all with late Cts ( $> 39$ ) indicative of possible low-level contamination from handling other  
257 positive samples. Sensitivity and specificity for detection of SARS-CoV-2 from swabs was 96.3% (95%  
258 confidence interval: 90.7-100%) and 95.2% (88.7-100%), respectively.

259 The cartridge Flu A assay missed detection of 2 out of the 14 positives which both had the lowest  
260 viral load of the Flu A samples (Ct  $> 35$ ), but yielded full concordance with negative samples, resulting in a  
261 sensitivity and specificity of 85.7 (64.3-100%) and 100%, respectively. For Flu B, all 4 positives were  
262 detected in cartridge with just one false-positive resulting in a specificity of 98.2% (95.5-100%). We have

263 excluded 5 negative samples and 4 SARS-CoV-2 positive samples that produced invalid cartridge results  
264 with no amplification of the control or any other targets (Supplementary Table 3). These invalid results  
265 may be a consequence of samples with relatively high levels of inhibitory compounds.

266



267  
268 **Fig. 5 | Clinical sample validation.** a-c, PCR cycle threshold (Ct) values for swabs ( $n = 116$ ) and saliva samples ( $n = 14$ )  
269 run in the multiplexed respiratory panel cartridges. Each point represents one sample with positive (+) and negative  
270 (-) classification determined by the benchtop comparator assay and denoted by color. All reactions with  
271 undetectable amplification are plotted with a Ct of 50 or higher. Cutoff Ct values for each assay are indicated with a  
272 horizontal dashed line. d-f, Corresponding receiver operator curves for the SARS-CoV-2, Flu A, and Flu B cartridge  
273 assays. Area under the curve (AUC) is indicated with 95% confidence interval.

## 274 Discussion

275 There is an urgent need for affordable and mass-produced testing options that can provide rapid,  
276 multiplexed results for identification of variants and to allow future screening of SARS-CoV-2 with other  
277 diseases that produce similar respiratory symptoms. Compared to the intricate multi-component designs  
278 of current commercially available cartridges, our simple thermoplastic cartridges demonstrate great  
279 potential as a highly cost-effective and scalable solution, which is amenable to industrial manufacturing  
280 techniques such as roll-to-roll molding, lamination, and die-cutting.

281 Numerous *in vitro* diagnostic companies and researchers propose the use of isothermal NATs as PCR  
282 alternatives to leverage the sensitivity of RNA-based detection while reducing cost with simplified  
283 instrumentation or “instrumentation-free” testing<sup>33,34</sup>. These tests have been developed using isothermal

284 techniques such as loop-mediated isothermal amplification (LAMP)<sup>35,36</sup>, recombinase polymerase  
285 amplification (RPA)<sup>37</sup>, or CRISPR-Cas based detection of viral RNA<sup>38</sup>. However, the need for manual  
286 processes to purify and concentrate sample RNA to achieve high sensitivity assays is often overlooked.  
287 Our magnetofluidic cartridges completely automate nucleic acid purification and concentration and  
288 minimize user intervention for reading results.

289 Our platform enables detection of multiple SARS-CoV-2 variants or other respiratory pathogens, while  
290 traditional rapid lateral-flow antigen tests and isothermal tests typically lack the ability to multiplex  
291 detection of several pathogens without either setting up multiple separate tests or requiring further post-  
292 processing steps for detection<sup>39-41</sup>. Post-processing of amplified products for readout of results adds an  
293 additional manual step which reduces the likelihood of adoption where a high-volume of tests requires  
294 minimal hands-on time. Furthermore, any handling of amplified product raises risks of contamination  
295 which would compromise test specificity.

296 Most low-cost rapid tests have minimal connectivity, making streamlined acquisition of patient results  
297 for surveillance difficult and can result in under-reporting of cases<sup>42</sup>. For widespread adoption, on-site  
298 multiplexed diagnostic methods need a user workflow as simple, fast, and affordable as lateral flow strips  
299 while maintaining connectivity for connecting to clinical databases for improving surveillance. This  
300 platform meets these needs in a compact user-friendly format that is compatible with various sample  
301 types including PBS, universal transport media, and saliva.

302 For realistic deployment, there are a few limitations to the current platform that must be addressed.  
303 In particular, the current cartridges are not shelf-stable for prolonged storage at room-temperature and  
304 are refrigerated or frozen prior to use. We are currently investigating techniques for built-in storage of  
305 dry reagents to allow stability at ambient conditions. To include testing for additional variants or  
306 respiratory pathogens, the cartridge would need to be expanded from the current 2-well design with  
307 additional PCR wells for higher multiplexing. Given the limited clinical sample volume available in this  
308 study, the assay design used a maximum 50  $\mu\text{L}$  input per sample, though further improvement to  
309 sensitivity to prevent false-negatives may be achieved by adapting the cartridge and binding buffer to be  
310 compatible with larger volumes of sample.

## 311 **Methods**

### 312 *RT-PCR assay composition*

313 A 7.5- $\mu\text{L}$  duplexed PCR probe assay was composed of 1X qScript XLT 1-Step RT-qPCR ToughMix  
314 (QuantaBio), 0.1 U/ $\mu\text{L}$  SpeedSTAR HS DNA polymerase (Takara Bio), 0.1 U/ $\mu\text{L}$  AccuStart II Taq DNA  
315 polymerase (QuantaBio), 1 mg/mL BSA (New England Biolabs), 0.1 % Tween-20 (Sigma Aldrich) and  
316 primer-probe pairs. For duplexed assay for N1 and control RNA, the assay contains 1  $\mu\text{M}$  each N1 primer,  
317 0.45  $\mu\text{M}$  each Luciferase primer, 1  $\mu\text{M}$  N1 probe and 0.25  $\mu\text{M}$  Luciferase probe. For duplexed assay for  
318 influenza A and influenza B, the assay contains 0.5  $\mu\text{M}$  each influenza A primer, 1  $\mu\text{M}$  each influenza B  
319 primer, 0.25  $\mu\text{M}$  influenza A probe and 0.5  $\mu\text{M}$  influenza B probe. For duplexed assay of SARS-CoV-2  
320 variant detection, the assay contains 0.67  $\mu\text{M}$  each Yale Spike  $\Delta 69-70$  primer, 0.3  $\mu\text{M}$  each Yale ORF1a  
321  $\Delta 3675-3677$  primer, 0.2  $\mu\text{M}$  Yale Spike  $\Delta 69-70$  probe and 0.2  $\mu\text{M}$  ORF1a  $\Delta 3675-3677$  probe. All  
322 oligonucleotides, including primers and fluorescently labeled DNA probe (sequences in Supplementary  
323 Table 4) were purchased from Integrated DNA Technologies.

## 324 *Cartridge fabrication and assembly*

325 The magnetofluidic cartridges were assembled from three thermoplastic layers (Supplementary  
326 Fig. 2). The bottom layer was fabricated by thermoforming 10 mil (~0.25 mm) thick polyethylene  
327 terephthalate glycol (PETG) sheet (Welch Fluorocarbon) over 3D-printed molds (Form 2, Formlabs)  
328 designed in Fusion 360 (Autodesk) to produce extruded wells. The middle layer was laser-cut from 0.75  
329 mm thick acrylic (ePlastics) with pressure-sensitive adhesive (PSA) (9472LE adhesive transfer tape, 3M)  
330 laminated on both sides. The top layer was laser-cut from 1.5 mm thick clear acrylic sheet (McMaster-  
331 Carr, USA) with Teflon tape (McMaster-Carr) laminated to one side and patterned by laser-etching.

332 To load reagents into the cartridge wells, the thermoformed section and acrylic middle layer were  
333 first joined with PSA, followed by dispensing 7.5  $\mu$ L PCR solution and 50  $\mu$ L wash buffer (W14,  
334 ChargeSwitch Total RNA Cell Kit, Invitrogen) into corresponding wells. With aqueous reagents pre-loaded,  
335 the cartridge was sealed by lamination with the top layer using the PSA on the other side of the middle  
336 layer. Once sealed, 420  $\mu$ L silicone oil (100 cSt, Millipore-Sigma) was injected through the sample injection  
337 port to cover the wells and fill the remaining space within the cartridge except for the first well. To create  
338 the wax plug in the first well, 40  $\mu$ L of molten docosane wax (Millipore-Sigma) was dispensed into the  
339 sample port and melted into the oil with a custom heating rig followed by cooling at room temperature  
340 to solidify. The cartridge was either used immediately or the sample injection port was sealed with  
341 adhesive tape (Scotch Magic Tape, 3M) and the cartridge stored on ice or frozen until use.

## 342 *Instrument design*

343 Laser-cut and 3D-printed housing and fixtures of the instrument was designed in Fusion 360.  
344 External walls were laser-cut from 1/8" thick acrylic (McMaster-Carr) and 3D-printed components were  
345 fabricated using an SLA (Form 2, Black Resin, Formlabs) or FDM printer (Prusa Mini, Prusament PETG,  
346 Prusa research). A 5-inch HDMI touchscreen (Elecrow) was mounted on top of the instrument to allow  
347 user input with the graphic user interface (GUI) designed in python using the Tkinter library. Motorized  
348 actuation of an arm containing opposing neodymium magnets (K&J Magnetics) was implemented with a  
349 micro servo motor (TowerPro SG51R) mounted on a carriage guided along two aluminum rails by a second  
350 servo motor (Hitec HS-485HB). A third servo motor (Hitec HS-485HB) pivoted an aluminum rod to swivel  
351 the heat blocks onto the cartridge. The sample well heat block was custom machined out of 6061  
352 aluminum and mounted onto a power resistor (Riedon PF1262-5RF1) with a steel M3 screw, while the  
353 PCR heat block was machined from 145 copper and mounted onto a thermoelectric element (Peltier Mini  
354 Module, Custom Thermoelectric) and heatsink using thermally conductive epoxy (Arctic Alumina Thermal  
355 Adhesive, Arctic Silver). Temperature of the heat blocks was monitored with a thermistor probe  
356 (GA100K6MCD1, TE Connectivity) epoxied directly adjacent to the wells. A 5V fan (Sunon) provided  
357 cooling to the heatsink.

358 Cartridges were illuminated using the red and blue channels of a 3-color RGB LED (Vollong) passed  
359 through a focusing lens (10356, Carclo) and dual bandpass excitation filter (59003m, Chroma).  
360 Fluorescence was captured with a CMOS camera (Pi NoIR Camera V2, Raspberry Pi) through a dual  
361 bandpass emission filter (535-700DBEM, Omega Optical). An Arduino Nano microcontroller coordinated  
362 control of the LEDs, fan, and motors, and a Raspberry Pi 3B+ ran the GUI, processed fluorescence images,  
363 monitored thermistor readings and provided current to the heat blocks via a motorshield (Dual  
364 TB9051FTG Motor Driver, Pololu). Power to the instrument was supplied with a 7.5V 45W wall adapter  
365 (MEAN WELL GST60A07-P1J).



### 366 *Cartridge limit of detection determination*

367 Limit of detection of the cartridge assays was determined using contrived specimens of viral  
368 particles spiked into nasopharyngeal swab or saliva samples. Gamma-irradiated viral particles from SARS-  
369 Related Coronavirus 2 (Isolate USA-WA1/2020), Influenza A/Puerto Rico/8/1934-9VMC2(NR-29027), and  
370 Influenza B virus B/Nevada/03/2011 (BV) (NR-44023) were obtained through the BEI Resources  
371 Repository and stored at -80 °C upon receipt. To prepare the contrived samples, a serial dilution of viral  
372 particles were spiked into pooled ( $n = 4$ ) clinical specimens (confirmed PCR-negative by the Johns Hopkins  
373 Clinical Microbiology Lab). Each concentration was tested a minimum of three times, and the limit of  
374 detection was determined when one of the replicates showed negative. Fifty microliters of swab eluate  
375 or five microliters of saliva was first mixed with 150  $\mu\text{L}$  magnetic bead binding buffer consisting of 0.67  
376 mg/mL ChargeSwitch beads, 0.5M KCl in 100mM aqueous MES, and  $10^5$  copies of Luciferase RNA internal  
377 control (Promega). The entire mixture of sample and bead buffer was loaded into the sample port of the  
378 cartridge followed by insertion into the instrument for processing.

### 379 *Clinical sample testing*

380 Clinical swab and saliva specimens were previously collected under Johns Hopkins IRB #00246027.  
381 Specimens were de-identified and blinded before testing. Nasopharyngeal swabs were eluted in 3 mL of  
382 Universal Transport Medium. Passive drooled saliva specimens were collected into an empty vessel. Five  
383 microliters of saliva was lysed with 50  $\mu\text{L}$  of aqueous buffer containing 1% Triton X-100 and 1.2 units of  
384 Thermolabile Proteinase K (P8111S, New England Biolabs). 50  $\mu\text{L}$  of swab eluate or 55  $\mu\text{L}$  of saliva with  
385 lysis buffer was mixed with 150  $\mu\text{L}$  magnetic bead binding buffer as previously described followed by  
386 loading the entire mixture into the sample port of the cartridge. The comparator assay for evaluation of  
387 clinical samples used a modified CDC testing protocol<sup>32</sup> for swabs (Supplementary Methods,  
388 Supplementary Fig. 8) and FDA EUA authorized SalivaDirect protocol<sup>43</sup> for saliva were employed to test all  
389 the clinical specimens on a Bio-Rad CFX96 Touch Real-Time PCR System as reference.

390 Testing of SARS-CoV-2 variants used RNA from clinical samples extracted using a chemagic 360  
391 instrument (PerkinElmer) with clades of each sample previously characterized by sequencing<sup>31</sup>. 2  $\mu\text{L}$  of  
392 extracted RNA was mixed with 150  $\mu\text{L}$  magnetic bead binding buffer following by loading into the sample  
393 port of the cartridge.

### 394 **Acknowledgements**

395 We thank Emily Chang for her help with the instrument's graphical user interface, and Shawna  
396 Lewis and Chun Huai (Alex) Luo for their assistance in collecting and preparing clinical samples. This work  
397 was supported by funding through the National Institutes of Health (R01AI138978, R01AI137272,  
398 R61AI154628).

### 399 **Competing Interests**

400 AYT and T-HW are coinventors on patent PCT/US2019/029937 "A Disposable Reagent Scaffold for  
401 Biochemical Process Integration".

### 402 **Supplementary Materials**

### 403 **Supplementary Methods**

404 **Supplementary Figures List**

405 **Fig. S1.** Loading Cartridges and Instrument Operation

406 **Fig. S2.** Cartridge Assembly

407 **Fig. S3.** Nucleic Acid Aliquoting with Sequential Elution

408 **Fig. S4.** Servo actuation for cartridge mounting and magnetic transfer

409 **Fig. S5.** Heat block simulation and design for rapid thermocycling

410 **Fig. S6.** Fluorescence processing algorithm

411 **Fig. S7.** Detection of SARS-CoV-2 in saliva

412 **Fig. S8.** Comparator assay evaluation

413

414 **Supplementary Tables List**

415 **Table 1.** Instrument bill of materials

416 **Table 2.** Specificity testing

417 **Table 3.** Clinical samples data

418 **Table 4.** PCR primers and probes

419

420 **Supplementary Movies**

421 **Movie S1.** On-cartridge sample processing

422

423 **References**

- 424 1. Sutton, D., Fuchs, K., D’Alton, M. & Goffman, D. Universal Screening for SARS-CoV-2 in Women  
425 Admitted for Delivery. *N. Engl. J. Med.* **382**, 2163–2164 (2020).
- 426 2. Kucharski, A. J. *et al.* Effectiveness of isolation, testing, contact tracing, and physical distancing on  
427 reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.  
428 *Lancet Infect. Dis.* **20**, 1151–1160 (2020).
- 429 3. Peto, J. *et al.* Weekly COVID-19 testing with household quarantine and contact tracing is feasible  
430 and would probably end the epidemic: Weekly Covid-19 testing. *R. Soc. Open Sci.* **7**, 0–3 (2020).
- 431 4. Galloway, S. E. *et al.* Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29,  
432 2020–January 12, 2021. *MMWR. Morb. Mortal. Wkly. Rep.* **70**, 95–99 (2021).
- 433 5. Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking  
434 epidemiological and genetic data. *medRxiv* 2020.12.30.20249034 (2021).

- 435 6. Lauring, A. S. & Hodcroft, E. B. Genetic Variants of SARS-CoV-2 - What Do They Mean? *JAMA - J.*  
436 *Am. Med. Assoc.* **325**, 529–531 (2021).
- 437 7. Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L. & Cevik, M. Public health actions to  
438 control new SARS-CoV-2 variants. *Cell* **184**, 1127–1132 (2021).
- 439 8. Veldhoen, M. & Simas, J. P. Endemic SARS-CoV-2 will maintain post-pandemic immunity. *Nat.*  
440 *Rev. Immunol.* (2021). doi:10.1038/s41577-020-00493-9
- 441 9. Gwinn, M., MacCannell, D. & Armstrong, G. L. Next-Generation Sequencing of Infectious  
442 Pathogens. *JAMA* **321**, 893 (2019).
- 443 10. Vogels, C. B. *et al.* PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern.  
444 *medRxiv* **351**, 2021.01.28.21250486 (2021).
- 445 11. Babiker, A., Myers, C. W., Hill, C. E. & Guarner, J. SARS-CoV-2 Testing. *Am. J. Clin. Pathol.* **153**,  
446 706–708 (2020).
- 447 12. WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.  
448 Interim guidance. (2020). Available at: <https://www.who.int/publications/i/item/10665-331501>.  
449 (Accessed: 6th December 2020)
- 450 13. McGarry, B. E., SteelFisher, G. K., Grabowski, D. C. & Barnett, M. L. COVID-19 Test Result  
451 Turnaround Time for Residents and Staff in US Nursing Homes. *JAMA Intern. Med.* **181**, 556  
452 (2021).
- 453 14. Peeling, R. W. *et al.* Serology testing in the COVID-19 pandemic response. *Lancet Infect. Dis.* **20**,  
454 e245–e249 (2020).
- 455 15. Foundation for Innovative New Diagnostics (FIND). FIND evaluation update: SARS-CoV-2 Assays.  
456 Available at: <https://www.finddx.org/covid-19/sarscov2-eval/>. (Accessed: 6th December 2020)
- 457 16. Weissleder, R., Lee, H., Ko, J. & Pittet, M. J. COVID-19 diagnostics in context. *Sci. Transl. Med.* **12**,  
458 1–7 (2020).
- 459 17. Pipper, J. *et al.* Catching bird flu in a droplet. *Nat. Med.* **13**, 1259–1263 (2007).
- 460 18. Shin, D. J. & Wang, T. H. Magnetic Droplet Manipulation Platforms for Nucleic Acid Detection at  
461 the Point of Care. *Ann. Biomed. Eng.* **42**, 2289–2302 (2014).
- 462 19. Zhang, Y. & Nguyen, N.-T. Magnetic digital microfluidics – a review. *Lab Chip* **17**, 994–1008  
463 (2017).
- 464 20. Egatz-Gómez, A. *et al.* Discrete magnetic microfluidics. *Appl. Phys. Lett.* **89**, (2006).
- 465 21. Shin, D. J. *et al.* Mobile nucleic acid amplification testing (mobiNAAT) for Chlamydia trachomatis  
466 screening in hospital emergency department settings. *Sci. Rep.* **7**, 4495 (2017).
- 467 22. Shin, D. J., Trick, A. Y., Hsieh, Y. H., Thomas, D. L. & Wang, T. H. Sample-to-Answer Droplet  
468 Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation. *Sci. Rep.* **8**, (2018).
- 469 23. Trick, A. Y. *et al.* A portable magnetofluidic platform for detecting sexually transmitted infections  
470 and antimicrobial susceptibility. *Sci. Transl. Med.* **13**, (2021).
- 471 24. Goldenberger, D. *et al.* Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay. *J.*

- 472 *Viol. Methods* **284**, 113925 (2020).
- 473 25. Liotti, F. M. *et al.* Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2  
474 molecular detection. *Clin. Microbiol. Infect.* **26**, 1699–1700 (2020).
- 475 26. Johnson, D. R., Lee, P. K. H., Holmes, V. F. & Alvarez-Cohen, L. An internal reference technique for  
476 accurately quantifying specific mRNAs by real-time PCR with application to the *tceA* reductive  
477 dehalogenase gene. *Appl. Environ. Microbiol.* **71**, 3866–3871 (2005).
- 478 27. Lu, X. *et al.* US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute  
479 Respiratory Syndrome Coronavirus 2. *Emerg. Infect. Dis.* **26**, 1654–1665 (2020).
- 480 28. Van Elden, L. J. R., Nijhuis, M., Schipper, P., Schuurman, R. & Van Loon, A. M. Simultaneous  
481 detection of influenza viruses A and B using real-time quantitative PCR. *J. Clin. Microbiol.* **39**,  
482 196–200 (2001).
- 483 29. Terrier, O. *et al.* Cellular transcriptional profiling in human lung epithelial cells infected by  
484 different subtypes of influenza A viruses reveals an overall down-regulation of the host p53  
485 pathway. *Viol. J.* **8**, 285 (2011).
- 486 30. World Health Organization. WHO information for the molecular detection of influenza viruses.  
487 (2020). Available at:  
488 [https://www.who.int/influenza/gisrs\\_laboratory/Protocols\\_influenza\\_virus\\_detection\\_Jan\\_2020.](https://www.who.int/influenza/gisrs_laboratory/Protocols_influenza_virus_detection_Jan_2020.pdf)  
489 pdf. (Accessed: 27th February 2021)
- 490 31. Thielen, P. M. *et al.* Genomic diversity of SARS-CoV-2 during early introduction into the  
491 Baltimore-Washington metropolitan area. *JCI Insight* **6**, (2021).
- 492 32. Centers for Disease Control and Prevention (CDC). CDC 2019–Novel Coronavirus (2019-nCoV)  
493 Real-Time RT-PCR Diagnostic Panel, Revision: 06. (2020).
- 494 33. Peto, J., Hunter, D. J., Riboli, E. & Griffin, J. L. Unnecessary obstacles to COVID-19 mass testing.  
495 *Lancet* **396**, 1633 (2020).
- 496 34. Woo, C. H., Jang, S., Shin, G., Jung, G. Y. & Lee, J. W. Sensitive fluorescence detection of SARS-  
497 CoV-2 RNA in clinical samples via one-pot isothermal ligation and transcription. *Nat. Biomed. Eng.*  
498 **4**, 1168–1179 (2020).
- 499 35. Dao Thi, V. L. *et al.* A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2  
500 RNA in clinical samples. *Sci. Transl. Med.* **12**, (2020).
- 501 36. Ganguli, A. *et al.* Rapid isothermal amplification and portable detection system for SARS-CoV-2.  
502 *Proc. Natl. Acad. Sci.* **117**, 22727–22735 (2020).
- 503 37. Behrmann, O. *et al.* Rapid Detection of SARS-CoV-2 by Low Volume Real-Time Single Tube  
504 Reverse Transcription Recombinase Polymerase Amplification Using an Exo Probe with an  
505 Internally Linked Quencher (Exo-IQ). *Clin. Chem.* **66**, 1047–1054 (2020).
- 506 38. Broughton, J. P. *et al.* CRISPR–Cas12-based detection of SARS-CoV-2. *Nat. Biotechnol.* **38**, 870–  
507 874 (2020).
- 508 39. Gootenberg, J. S. *et al.* Multiplexed and portable nucleic acid detection platform with Cas13,  
509 Cas12a and Csm6. *Science (80-. ).* **360**, 439–444 (2018).

- 510 40. Xu, G. *et al.* Paper-Origami-Based Multiplexed Malaria Diagnostics from Whole Blood. *Angew.*  
511 *Chemie* **128**, 15476–15479 (2016).
- 512 41. Daher, R. K., Stewart, G., Boissinot, M. & Bergeron, M. G. Recombinase polymerase amplification  
513 for diagnostic applications. *Clin. Chem.* **62**, 947–958 (2016).
- 514 42. Pradhan, R., Weber, L. & Recht, H. Lack of Antigen Test Reporting Leaves Country ‘Blind to the  
515 Pandemic’. *Kaiser Health News* (2020). Available at: [https://khn.org/news/lack-of-antigen-test-](https://khn.org/news/lack-of-antigen-test-reporting-leaves-country-blind-to-the-pandemic/)  
516 [reporting-leaves-country-blind-to-the-pandemic/](https://khn.org/news/lack-of-antigen-test-reporting-leaves-country-blind-to-the-pandemic/). (Accessed: 21st April 2021)
- 517 43. FDA. Yale School of Public Health, Department of Epidemiology of Microbial Diseases SalivaDirect  
518 assay EUA Summary – Updated April 9, 2021. Available at:  
519 <https://www.fda.gov/media/141192/download>. (Accessed: 21st April 2021)